师从诺奖得主David Baker，杨为博士全职加入深圳医学科学院，聚焦于从头设计蛋白质药物

Core Viewpoint - The establishment of a protein drug design research group at Shenzhen Medical Academy by Dr. Yang Wei, focusing on innovative protein-protein interaction design methods for cancer immunotherapy [2][3]. Group 1: Research Background - Dr. Yang Wei obtained his Ph.D. in Biology from Tsinghua University in 2019 and has conducted postdoctoral research at the University of Washington, collaborating with notable figures in protein design [2]. - His research emphasizes the development of new computational design methods for protein interactions, particularly in the context of immune regulation and cancer immunotherapy [2][3]. Group 2: Research Objectives - The protein drug design group aims to create new drug design methods and validation platforms to support the development of novel protein drugs [3]. - The group will focus on designing highly selective biomolecules for cancer immunotherapy, enhancing targeting while reducing systemic toxicity [3]. Group 3: Recent Research Publication - On February 26, 2025, Dr. Yang published a paper in Nature Communications titled "Design of high-affinity binders to immune modulating receptors for cancer immunotherapy," detailing his research direction [5]. - The study highlights the importance of immune receptors in maintaining internal balance and their role in cancer immunotherapy, which has significantly improved patient survival rates [9]. Group 4: Targeted Protein Design - The research team is developing a specialized 5-helix concave scaffold (5HCS) to create high-affinity protein binders targeting key immune receptors involved in cancer therapy, such as TGFβRII, CTLA-4, and PD-L1 [10][11]. - The designed protein binders have shown low nanomolar to picomolar affinity and strong biological activity, indicating their potential for therapeutic applications [11].